KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,007,953 | +3.7% | 104,668 | -3.1% | 0.01% | 0.0% |
| Q2 2023 | $971,775 | +23.8% | 107,975 | +8.1% | 0.01% | +25.0% |
| Q1 2023 | $784,986 | +24.3% | 99,871 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $631,472 | -54.5% | 93,413 | -2.3% | 0.00% | -55.6% |
| Q3 2022 | $1,387,000 | +114.0% | 95,586 | +45.1% | 0.01% | +125.0% |
| Q2 2022 | $648,000 | +92.3% | 65,882 | +187.8% | 0.00% | +100.0% |
| Q1 2022 | $337,000 | +59.0% | 22,893 | +42.7% | 0.00% | +100.0% |
| Q4 2021 | $212,000 | +2.4% | 16,048 | +35.0% | 0.00% | 0.0% |
| Q3 2021 | $207,000 | – | 11,887 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |